Form 15-12G BIOLIFE SOLUTIONS INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall Street ends down sharply, worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 001-36362
BioLife Solutions, Inc.
(BioLife Solutions, LLC, as successor by merger to BioLife Solutions, Inc.)
(Exact name of registrant as specified in its charter)
c/o Repligen Corporation
41 Seyon Street, Bldg. 1, Suite 100
Waltham, MA
(781) 250-0111
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule 12g-4(a)(1) |
☒ | |||
| Rule 12g-4(a)(2) |
☐ | |||
| Rule 12h-3(b)(1)(i) |
☒ | |||
| Rule 12h-3(b)(1)(ii) |
☐ | |||
| Rule 15d-6 |
☐ | |||
| Rule 15d-22(b) |
☐ |
Approximate number of holders of record as of the certification or notice date: 1*
| * | On October 6, 2026, pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026, by and among Repligen Corporation, a Delaware corporation (“Repligen”), BioLife Solutions, Inc., a Delaware corporation (“BioLife”), Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Repligen (“Merger Sub 1”), and Bravo Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Repligen (“Merger Sub 2”), Merger Sub 1 merged with and into BioLife with BioLife surviving as a direct, wholly owned subsidiary of Repligen, and immediately thereafter, BioLife merged with and into Merger Sub 2, with Merger Sub 2 surviving as a direct, wholly owned subsidiary of Repligen, and renamed as “BioLife Solutions, LLC.” |
Pursuant to the requirements of the Securities Exchange Act of 1934, BioLife Solutions, LLC (as successor by merger to BioLife Solutions, Inc.) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
Date: October 16, 2026
| BIOLIFE SOLUTIONS, LLC | ||
| as successor by merger to BioLife Solutions, Inc. | ||
| By: | /s/ George Scott | |
| Name: | George Scott | |
| Title: | President and Authorized Person | |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies
- Constellation Software Inc. Announces Conference Call to Discuss Third Quarter Results
- Granite REIT Declares Distribution for October 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
